之前的研究已经表明，D. viscosa植物提取物常用于治疗多种疾病。因此，本研究的目的是调查对糖尿病引起的大鼠肝脏和肾脏损伤的任何额外潜在影响。为了引起1型糖尿病，给予链脲佐菌素（STZ）（60mg/kg/天）单剂量。然后，糖尿病大鼠在接下来的四周内口服D. viscosa剂量为150和300mg/kg/天。治疗结束后，收集血液、肝脏和肾脏组织进行检查。分析血清血脂谱、肝肾功能以及血液生化。此外，还估计了血清中肿瘤坏死因子-alpha（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-1 beta（IL-1β）、前列腺素E-2（PGE-2）和一氧化氮（NO）的水平。在肝脏和肾脏样本中，分析了硫代巴比妥酸反应物（TBARs）和还原型谷胱甘肽（GSH），以及促炎细胞因子和谷胱甘肽过氧化物酶（GPx）、谷胱甘肽还原酶（GR）、谷胱甘肽-S-转移酶（GST）、过氧化氢酶（CAT）和超氧化物歧化酶（SOD）的酶活性。还观察了肝脏和肾脏切片的组织学变化。我们的研究结果表明，D. viscosa显著降低了血液、肾脏和肝脏组织中的促炎指标，降低了血糖水平，并恢复了胰岛素水平和脂质谱。此外，它显著提高了抗氧化酶SOD、CAT、GPx和GST的活性，同时显著降低了TBARs水平。这些组织中的上述生化变化得到了组织学变化的进一步支持。这些发现表明，D. viscosa对STZ引起的高血糖、异常脂质合成和氧化应激具有保护作用，并且这些益处可能是通过与多种靶点相互作用以增加肝脏和肾脏中抗氧化酶的水平来介导的。其作用方式和作为治疗由糖尿病引起的各种代谢问题的药物的安全性需要进一步研究。© 2023 The Authors.

Previous investigations have shown that D. viscosa herbal extract is often used to treat a variety of diseases. Therefore, the purpose of this study was to investigate any additional potential impacts on rat liver and kidney damage induced by diabetes. Streptozotocin (STZ) (60 mg/kg/day) was given as a single dosage to cause type 1 diabetes. After then, diabetic rats received oral doses of D. viscosa for four weeks at 150 and 300 mg/kg/day. Blood, liver, and kidney tissues were collected at the end of the treatment and examined. Analysis was made of the serum lipid profile, liver, and kidney functions, as well as blood biochemistry. Moreover, the levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), prostaglandin E-2 (PGE-2), and nitric oxide (NO) were estimated in serum. In liver and kidney samples, thiobarbituric acid reactive substances (TBARs) and reduced glutathione (GSH), as well as the pro-inflammatory cytokines and enzymatic activities of glutathione peroxidase (GPx), glutathione reeducates (GR), glutathione-S-transferase (GST), catalase (CAT), and superoxide dismutase (SOD) were analyzed. Histological changes in liver and kidney cross-sections were also observed. Our findings demonstrated that D. viscosa dramatically decreased pro-inflammatory indicators in blood, kidney, and liver tissues as well as blood glucose, and restored insulin levels, and lipid profiles. Additionally, it significantly raises the antioxidant enzyme activity SOD, CAT, GPx, and GST, while significantly lowering TBARs levels. The above-mentioned biochemical changes that took place in tissues were further supported by histological alterations. These findings imply that D. viscosa protects against STZ-induced hyperglycemia, aberrant lipid synthesis, and oxidative stress and that these benefits may be mediated by interacting with various targets to increase the levels of antioxidant enzymes in the liver and kidneys. Its mode of action and safety for use as medicine against various metabolic problems caused by diabetes require more research.© 2023 The Authors.